| 0.3106 0.066 (26.78%) | 01-10 00:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Sema4 Holdings Corp., known in the market as Sema4, functions as a health information enterprise committed to leveraging data to enhance the diagnosis, treatment, and prevention of illnesses. A primary offering is Centrellis, an AI-driven health intelligence platform that furnishes extensive insights to biopharmaceutical firms, thereby streamlining the entire lifecycle of drug discovery, development, and commercialization. Centrellis further provides practical analytics, assistance for pre-clinical and clinical trials, and state-of-the-art sequencing capabilities. The company also markets Sema4 Signal, a product designed to facilitate and advance precise oncology care, covering everything from prevention strategies to active treatment and managing remission. Additionally, their diagnostic services encompass carrier screening, non-invasive prenatal assessments, newborn screening, and hereditary cancer testing, complemented by their COVID-19 testing solutions. Sema4 Holdings Corp. was established in 2020 and is based in Stamford, Connecticut.
Fri, 04 Sep 2026
Sema4 Holdings Corp. Class A (SMFR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Tue, 18 Jan 2022
Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform - OPKO Health, Inc.
Wed, 06 Oct 2021
Cathie Wood’s ARK Invest Sells Nearly a Million Shares of Skillz - 24/7 Wall St.
Thu, 22 Jul 2021
Stamford-based Sema4 goes public, expects to raise $500M - Stamford Advocate
Thu, 22 Jul 2021
Stamford health data firm Sema4 to cash in on Wall Street’s exploding capital markets and go public - Hartford Courant
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|